IETH2018 8--P a disease with disturbed plateleta diseasewith func Bemiparin sodium5000IU2x1was started this risk of bleeding dueto druginterac risk of dosagefor hadbeenorganized thispa twicedaily des e adverse Decrease inplatelet values is oneoftherare sidee Discussion: 650000-700000. LMWHmedica the has beenusing thrombocytosis by adding LMWH into the treatment. We observed afavorable decrease in thrombocyte levels of the pa Conclusion: response. However, thepa sent bythemicroarray method. homozygous, Factor Vleidengene muta The pa The pa parameters suchasurea, crea Laboratory: with USG) treatment hasbeen added withthedossage 2x1,then3x1inaddi later, platelet value was 1750000,thepa Physical examina treatment.  to lower extremity deepvein (DVT) in June2008.Thepa Medical Story (anamnesis): and Research Hospital thehematology clinicsinceMay 2016. Numune Educa pa Because ofthevarious reasons, there may besomechanges amongtheLMWHsregarding the For the pa the For Case report: proximal venous thrombosis and have beenshownto furtherinhibittheinvivo genera Introduc Low molecularweightheparins have beenfound at least ase me inthelower extremity inSeptember 2013, this  A FAVORABLE DECREASE INTHROMBOCYTE LEVELSCAUSED BY LMWH TREATMENT FOR ADVT ent’sclinical follow-ups. University ofHealthSciencesÜmraniye Educa Hakan Keski Use ofLMWH forthemanagementof VTEinclinicalpractice   ent hadrecurrent DVT incident again inJuly2017.Factor IIG20210Agene muta ent ini   c o MH o consolida ofLMWHsfor ect on:  ent JAK2 V617Fposi At the the At A 53-year-old malepa   PATIENT REFRACTER ESSENTIAL THROMBOCYTOSIS:A WITH case report ally received ASA 100mgandhydroxyurea 500mg3x1was alsogiven and3months  on andResearch Hospital in2006.Pa  ent's platelet count was decreased on:  me ofdiagnosis,WBC10880,Hgb:15,9g/ Splenomegaly was con One month 3800IUtreatment was given to pa  nine, AST, ALT were normal.    onduring the 3 months ,pa the3months onduring ve essen ons such as 100mg ASA was also minimized. Whilethepa also was ASA such as 100mg ons   Hakan Keski, MD, Hematology n uhasETaccompanying thepa ons such ent, pa  on ofourtreatment and to increase inthetreatment   on heterozygous mutant isdetected inthegene  ent hasbeenaccepted asrefractor and anagrelide al thrombocytosis (ET)was diagnosedinHaydarpa   me inthelast deepvein thrombosis a ent weight: 88kg   rmed withpalpa  ent. Furthermore bythisposology, thepa ects of LMWHs.In ourcase we evaluated this ects ofLMWHs.In  on andResearch Hospital, ClinicofHematology  ntherange of1200000-1300000. in  me 6000IUwas given as ent hasbeenfollowed in Ümraniye Educa  ent’s platelet counts ranged from   ec ent withcytoreduc dl Hct%46Plt:1820000,biochemical   on for 2cm(168mmmeasured ve asunfrac  on to thecurrent treatment.  ent hadDVT for thesecond  ent ,bemiparinsodium ent  oned in oned heparin   ack.Due to Hematology and Thrombosis in Encounter International 1st ve-resistant ve-resistant    ent’s ent’s ent on  c tests  a  ent due   on on.